3-(1-Pyrazolyl)-pyridazine derivatives
    1.
    发明授权
    3-(1-Pyrazolyl)-pyridazine derivatives 失效
    3-(1-吡唑基) - 哒嗪衍生物

    公开(公告)号:US4251658A

    公开(公告)日:1981-02-17

    申请号:US914084

    申请日:1978-06-09

    CPC分类号: C07D403/04

    摘要: 3-(1-Pyrazolyl)-pyridazine derivatives of the formula I, or pharmaceutically acceptable acid addition salts thereof, which decrease high blood pressure and inhibit catabolism or prostaglandins, ##STR1## wherein R.sup.1 is hydrogen or C.sub.1-4 alkyl,R.sup.2 is hydrogen, cyano, carboxyl, carbamoyl, carbaxoyl or C.sub.1-4 alkoxycarbonyl,R.sup.3 is hydrogen or chlorine or --NR.sup.4 NHR.sup.5 or NR.sup.6 R.sup.7, wherein R.sup.4 and R.sup.5 are each hydrogen or C.sub.1-4 alkyl, wherein R.sup.6 and R.sup.7 are each hydrogen or C.sub.1-5 alkyl, C.sub.1-5 hydroxyalkyl, C.sub.3-7 cycloalkyl, phenyl or benzyl, or benzyl or phenylethyl substituted with one or two chlorine atoms or methoxy groups, or a furylmethyl, pyridylmethyl, pyrrolidine or piperazine ring, or when R.sup.7 is hydrogen, R.sup.6 is --(CH.sub.2).sub.n --NR.sup.4 R.sup.5 wherein n is an integer from 1 to 3.

    摘要翻译: 降低高血压并抑制分解代谢或前列腺素的式I的3-(1-吡唑基) - 哒嗪衍生物或其药学上可接受的酸加成盐,其中R 1是氢或C 1-4烷基, R2是氢,氰基,羧基,氨基甲酰基,碳酰基或C1-4烷氧基羰基,R3是氢或氯或-NR4NHR5或NR6R7,其中R4和R5分别是氢或C1-4烷基,其中R6和R7各自是氢或C1 或烷基,C 1-5羟基烷基,C 3-7环烷基,苯基或苄基,或被一个或两个氯原子或甲氧基取代的苄基或苯乙基,或呋喃基甲基,吡啶基甲基,吡咯烷或哌嗪环,或者当R7为氢时, R 6为 - (CH 2)n -NR 4 R 5,其中n为1至3的整数。

    3-(1-Pyrazolyl)-pyridazine derivatives and hypotensive compositions
thereof
    2.
    发明授权
    3-(1-Pyrazolyl)-pyridazine derivatives and hypotensive compositions thereof 失效
    3-(1-吡唑基) - 哒嗪衍生物及其低血压组合物

    公开(公告)号:US4224325A

    公开(公告)日:1980-09-23

    申请号:US923623

    申请日:1978-07-11

    摘要: The invention relates to compounds of general formula ##STR1## wherein R.sup.1 stands for a hydrogen atom or a C.sub.1-6 alkyl-, a C.sub.2-4 hydroxyalkyl, a C.sub.3-6 cycloalkyl or a phenyl group,R.sup.2 stands for a hydrogen, fluorine, chlorine or bromine atom or a C.sub.1-6 alkyl, a C.sub.2-4 hydroxyalkyl, a nitro or an --NR.sup.5 R.sup.6 group, wherein R.sup.5 and R.sup.6 may have the same or different meaning and stand each for a hydrogen atom or a C.sub.1-4 alkyl or a C.sub.2-4 hydroxyalkyl group,R.sup.3 stands for a hydrogen atom or a C.sub.1-6 alkyl, a C.sub.2-4 hydroxyalkyl, a C.sub.3-6 cycloalkyl or a phenyl group, a chlorine atom or a hydroxyl, amino or methoxy group,R.sup.4 stands for a carbamoyl, a cyano or an --NR.sup.7 --NHR.sup.8 group, wherein R.sup.7 and R.sup.8 may have the same or different meaning and stand each for a hydrogen atom or a C.sub.1-4 alkyl, a C.sub.2-4 hydroxyalkyl, a C.sub.1-4 alkoxycarbonyl or an --NR.sup.9 R.sup.10 group, wherein R.sup.9 and R.sup.10 may have the same or different meaning and stand each for a hydrogen atom or a C.sub.1-5 alkyl, a C.sub.2-4 hydroxyalkyl, a C.sub.3-6 cycloalkyl, a phenyl or a benzyl group, or --NR.sup.9 R.sup.10 may represent a morpholine, piperidine or piperazine ring,and their pharmaceutically acceptable acid-addition salts. Furthermore, the invention relates to a process for preparing these compounds.The novel compounds of general formula I have valuable pharmacological properties. Thus they show a considerable hypotensive effect and are capable to inhibit enzymes regulating the catabolism of prostaglandins.

    摘要翻译: 本发明涉及通式为“IMAGE”的化合物,其中R1代表氢原子或C1-6烷基,C2-4羟基烷基,C3-6环烷基或苯基,R2代表氢,氟, 氯或溴原子或C 1-6烷基,C 2-4羟基烷基,硝基或-NR 5 R 6基团,其中R 5和R 6可以具有相同或不同的含义,并且各自代表氢原子或C 1-4烷基或 C2-4羟基烷基,R3代表氢原子或C1-6烷基,C2-4羟烷基,C3-6环烷基或苯基,氯原子或羟基,氨基或甲氧基,R4代表 对于氨基甲酰基,氰基或-NR 7 -NHR 8基团,其中R 7和R 8可以具有相同或不同的含义,各自代表氢原子或C 1-4烷基,C 2-4羟烷基,C 1-4烷氧基羰基 或-NR 9 R 10基团,其中R 9和R 10可以具有相同或不同的含义,并且各自表示氢原子或C 1-5烷基,C 2-4的羟基烷基,C 3-6环烷基,苯基或苯基 或-NR9R10可以表示吗啉,哌啶或哌嗪环及其药学上可接受的酸加成盐。 此外,本发明涉及一种制备这些化合物的方法。 通式Ⅰ的新化合物具有有价值的药理学性质。 因此,它们显示出相当的降血压作用,并且能够抑制调节前列腺素分解代谢的酶。